利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.023 秒)

    Method of scintigraphy
    4.
    发明授权
    Method of scintigraphy 有权
    闪烁法的方法

    公开(公告)号：US07947673B2

    公开(公告)日：2011-05-24

    申请号：US12091970

    申请日：2006-10-30

    申请人： Hanspeter Nick ,  Rene Lattmann

    发明人： Hanspeter Nick ,  Rene Lattmann

    IPC分类号： A61K31/555 ,  C07D249/08

    CPC分类号： C07D249/08 ,  A61K45/06 ,  A61K51/0478

    摘要： The invention relates to combination comprising a pharmaceutically acceptable preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a gallium and its use in diagnosis. The invention also pertains to the use of a compound of formula I or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of an excess iron overload in the human or animal body whereby said body is undergoing gallium scintigraphy and whereby the treatment removing said excess of iron is interrupted for a period of 2 to 10 days prior to the gallium scintigraphy and resumed after the gallium scintigraphy readings.

    摘要翻译： 本发明涉及包含式（I）化合物的药学上可接受的制剂或其药学上可接受的盐和镓的组合及其在诊断中的用途。 本发明还涉及式I化合物或其药学上可接受的盐在制备用于治疗人或动物身体中过量铁超载的药物中的用途，由此所述身体经历镓闪烁扫描，并且其中 在镓闪烁扫描术之前，将所述过量铁除去处理2至10天的时间，并在镓闪烁扫描读数之后恢复。

    Method of Scintigraphy
    5.
    发明申请
    Method of Scintigraphy 有权
    扫描方法

    公开(公告)号：US20080279962A1

    公开(公告)日：2008-11-13

    申请号：US12091970

    申请日：2006-10-30

    申请人： Hanspeter Nick ,  Rene Lattmann

    发明人： Hanspeter Nick ,  Rene Lattmann

    IPC分类号： A61K33/24 ,  A61K31/4196 ,  C07F15/00

    CPC分类号： C07D249/08 ,  A61K45/06 ,  A61K51/0478

    摘要： The invention relates to combination comprising a pharmaceutically acceptable preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a gallium and its use in diagnosis. The invention also pertains to the use of a compound of formula I or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of an excess iron overload in the human or animal body whereby said body is undergoing gallium scintigraphy and whereby the treatment removing said excess of iron is interrupted for a period of 2 to 10 days prior to the gallium scintigraphy and resumed after the gallium scintigraphy readings.

    摘要翻译： 本发明涉及包含式（I）化合物的药学上可接受的制剂或其药学上可接受的盐和镓的组合及其在诊断中的用途。 本发明还涉及式I化合物或其药学上可接受的盐在制备用于治疗人或动物身体中过量铁超载的药物中的用途，由此所述身体经历镓闪烁扫描，并且其中 在镓闪烁扫描术之前，将所述过量铁除去处理2至10天的时间，并在镓闪烁扫描读数之后恢复。

    Treatment of Liver Diseases in Which Iron Plays a Role in Pathogenesis
    6.
    发明申请
    Treatment of Liver Diseases in Which Iron Plays a Role in Pathogenesis 审中-公开
    治疗肝脏在发病机制中发挥作用的肝病

    公开(公告)号：US20080199428A1

    公开(公告)日：2008-08-21

    申请号：US11913678

    申请日：2006-05-30

    申请人： Daniele M. Alberti ,  Peter Marks ,  Hanspeter Nick ,  Lisa Grace Rojkjaer

    发明人： Daniele M. Alberti ,  Peter Marks ,  Hanspeter Nick ,  Lisa Grace Rojkjaer

    IPC分类号： A61K31/4196 ,  A61K38/21 ,  A61P43/00

    CPC分类号： A61K31/4196

    摘要： The invention relates to the use of 4-[3,5-Bis-(2-hydroxyphenyl)-[1,2,4]-triazol-1-yl]benzoic acid (hereinafter referred to as “Compound I”) for the manufacture of pharmaceutical compositions for the treatment of liver diseases in humans in which iron plays a role in pathogenesis, including viral diseases, such as chronic hepatitis C, optionally in conjunction with antiviral agents and for the treatment of non viral diseases, such as non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.

    摘要翻译： 本发明涉及4- [3,5-双 - （2-羟基苯基） - [1,2,4] - 三唑-1-基]苯甲酸（以下称为“化合物I”）用于 制造用于治疗人在其中发挥铁作用的人类肝病的药物组合物，包括病毒性疾病如慢性丙型肝炎，任选地与抗病毒剂联合用于治疗非病毒性疾病，例如非病毒性疾病， 酒精性脂肪性肝炎和非酒精性脂肪性肝病。

    TREATMENT OF LIVER DISEASES IN WHICH IRON PLAYS A ROLE IN PATHOGENESIS
    7.
    发明申请
    TREATMENT OF LIVER DISEASES IN WHICH IRON PLAYS A ROLE IN PATHOGENESIS 审中-公开
    治疗肝脏中发生肝病的病因

    公开(公告)号：US20100098662A1

    公开(公告)日：2010-04-22

    申请号：US12641690

    申请日：2009-12-18

    申请人： Daniele M. Alberti ,  Peter Marks ,  Hanspeter Nick ,  Lisa Grace Rojkjaer

    发明人： Daniele M. Alberti ,  Peter Marks ,  Hanspeter Nick ,  Lisa Grace Rojkjaer

    IPC分类号： A61K38/21 ,  A61K31/4196 ,  A61P1/16 ,  A61K31/70

    CPC分类号： A61K31/4196

    摘要： The invention relates to the use of 4-[3,5-Bis-(2-hydroxyphenyl)-[1,2,4]-triazol-1-yl]benzoic acid (hereinafter referred to as “Compound I”) for the manufacture of pharmaceutical compositions for the treatment of liver diseases in humans in which iron plays a role in pathogenesis, including viral diseases, such as chronic hepatitis C, optionally in conjunction with antiviral agents and for the treatment of non viral diseases, such as non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.

    摘要翻译： 本发明涉及4- [3,5-双 - （2-羟基苯基） - [1,2,4] - 三唑-1-基]苯甲酸（以下称为“化合物I”）用于 制造用于治疗人在其中发挥铁作用的人类肝病的药物组合物，包括病毒性疾病如慢性丙型肝炎，任选地与抗病毒剂联合用于治疗非病毒性疾病，例如非病毒性疾病， 酒精性脂肪性肝炎和非酒精性脂肪性肝病。

    TREATMENT OF ENDOCRINE DYSFUNCTION USING IRON CHELATORS
    9.
    发明申请
    TREATMENT OF ENDOCRINE DYSFUNCTION USING IRON CHELATORS 审中-公开
    使用铁器治疗内分泌功能障碍

    公开(公告)号：US20100004303A1

    公开(公告)日：2010-01-07

    申请号：US12375547

    申请日：2007-08-03

    申请人： Ioav Cabantchik ,  Hanspeter Nick

    发明人： Ioav Cabantchik ,  Hanspeter Nick

    IPC分类号： A61K31/4196 ,  A61P3/10

    CPC分类号： A61K31/4196

    摘要： The invention relates to the use of an iron chelator for the treatment or prevention of pathologies due to iron loading, e.g. related to a dysfunction, in particular a reduction or inhibition, of the secretory function of cells from endocrine glands, in the human or animal body.

    摘要翻译： 本发明涉及铁螯合剂用于治疗或预防由铁负荷引起的病理学的用途，例如， 与人或动物体内的内分泌腺细胞的分泌功能的功能障碍特别是减少或抑制有关。